AC Immune shares are trading higher after the company's partner, Life Molecular Imaging, received a FDA Fast Track designation for the PI-2620 Tau-PET Diagnostic in three neurodegenerative conditions.
Portfolio Pulse from Benzinga Newsdesk
AC Immune's shares rose following the FDA Fast Track designation for the PI-2620 Tau-PET Diagnostic, developed with partner Life Molecular Imaging, for three neurodegenerative conditions.
August 28, 2024 | 4:30 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
AC Immune's stock is positively impacted by the FDA Fast Track designation for the PI-2620 Tau-PET Diagnostic, developed with Life Molecular Imaging, enhancing its potential in neurodegenerative diagnostics.
The FDA Fast Track designation is a significant regulatory milestone that can expedite the development and review process, potentially leading to earlier market entry. This news is likely to boost investor confidence in AC Immune's prospects in the neurodegenerative diagnostics market.
CONFIDENCE 90
IMPORTANCE 70
RELEVANCE 80